Acute myeloid leukemia with a ZMYND11::MBTD1 fusion gene following chemotherapy and radiotherapy for breast cancer: A case report

IF 0.7 Q4 HEMATOLOGY Leukemia Research Reports Pub Date : 2024-01-01 DOI:10.1016/j.lrr.2024.100478

Hidetsugu Kawai , Sawako Shiraiwa , Daisuke Ogiya , Masako Toyosaki , Shinichiro Machida , Rikio Suzuki , Makoto Onizuka , Yoshiaki Ogawa , Hiroshi Kawada

{"title":"Acute myeloid leukemia with a ZMYND11::MBTD1 fusion gene following chemotherapy and radiotherapy for breast cancer: A case report","authors":"Hidetsugu Kawai , Sawako Shiraiwa , Daisuke Ogiya , Masako Toyosaki , Shinichiro Machida , Rikio Suzuki , Makoto Onizuka , Yoshiaki Ogawa , Hiroshi Kawada","doi":"10.1016/j.lrr.2024.100478","DOIUrl":null,"url":null,"abstract":"<div>The t(10;17)(p15;q21) translocation is a very rare recurrent cytogenetic aberration, and produced ZMYND11::MBTD1 fusion gene. To date, nine cases of acute leukemia with the t(10;17)(p15;q21) translocation have been reported, but the case of AML with ZMYND11::MBTD1 after chemotherapy and radiotherapy have not been reported. Epirubicin-based chemotherapy or radiotherapy for breast cancer increases the risk of developing secondary leukemia. We report a case of AML with the ZMYND11::MBTD1 fusion gene that developed after epirubicin-based chemotherapy and radiotherapy for breast cancer. previous chemotherapy and radiotherapy may be associated with poor prognosis of AML with ZMYND11/MBTD1.</div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"22 ","pages":"Article 100478"},"PeriodicalIF":0.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000682/pdfft?md5=ce7223922598a44c6fcf072460505d41&pid=1-s2.0-S2213048924000682-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213048924000682","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The t(10;17)(p15;q21) translocation is a very rare recurrent cytogenetic aberration, and produced ZMYND11::MBTD1 fusion gene. To date, nine cases of acute leukemia with the t(10;17)(p15;q21) translocation have been reported, but the case of AML with ZMYND11::MBTD1 after chemotherapy and radiotherapy have not been reported. Epirubicin-based chemotherapy or radiotherapy for breast cancer increases the risk of developing secondary leukemia. We report a case of AML with the ZMYND11::MBTD1 fusion gene that developed after epirubicin-based chemotherapy and radiotherapy for breast cancer. previous chemotherapy and radiotherapy may be associated with poor prognosis of AML with ZMYND11/MBTD1.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

乳腺癌化疗和放疗后出现 ZMYND11::MBTD1 融合基因的急性髓性白血病：病例报告

t(10;17)(p15;q21)易位是一种非常罕见的复发性细胞遗传畸变，并产生ZMYND11::MBTD1融合基因。迄今为止，已有九例 t(10;17)(p15;q21)易位的急性白血病病例报道，但化疗和放疗后出现 ZMYND11::MBTD1 融合基因的急性髓细胞性白血病病例尚未见报道。以表柔比星为基础的乳腺癌化疗或放疗会增加罹患继发性白血病的风险。我们报告了一例乳腺癌患者在接受以表柔比星为基础的化疗和放疗后出现的ZMYND11::MBTD1融合基因型急性髓细胞白血病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊